Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.41)
# 3,968
Out of 4,735 analysts
4
Total ratings
33.33%
Success rate
-14.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $40.91 | +122.44% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $1.53 | +684.31% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $96.24 | +16.38% | 1 | Oct 28, 2022 |
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $40.91
Upside: +122.44%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $1.53
Upside: +684.31%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $96.24
Upside: +16.38%